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the proportion of patients undergoing corneal transplantation.
Study designs and other criteria for inclusion in the review
The evidence came from several publications of the same randomised, clinical trial. Thus, a review of the literature was not undertaken.
Sources searched to identify primary studies
Not relevant.
Criteria used to ensure the validity of primary studies
The validity of the primary study was ensured by the design of the trial.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two primary studies were used.
Methods of combining primary studies
Not stated.
Investigation of differences between primary studies
Results of the review
The annual probability of recurrent HSV disease decreased by a relative risk reduction of 45%, from 32% among placebo-treated patients to 19% among acyclovir-treated patients.
Four per cent of patients discontinued treatment due to adverse events. Fifty per cent of adverse events were gastrointestinal and 10% were rashes. Other adverse events included dizziness, weight gain, headache, fatigue, sexual dysfunction, memory loss, anxiety, tinnitus and hair loss.
The annual probability of recurrent SK in patients who had a history of prior SK decreased by a relative risk of 43%, from 28% in placebo-treated patients to 14% in acyclovir-treated patients.
The proportion of patients undergoing corneal transplantation was 1.4%.
Given these data, the following probabilities were used in the decision tree: the probability of adverse events with acyclovir was 4%; the probability of infections was 32% for patients receiving no prophylaxis, 18% when acyclovir was given to all patients without adverse events, 25% when acyclovir was given to all patients and caused adverse events, and 23% when acyclovir was given to patients with a history of SK; the probability of SK was 48% in all branches; the probability of undergoing surgery was 2% for patients receiving no prophylaxis or when acyclovir was given to all
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Measure of benefits used in the economic analysis
The summary benefit measure used was the number of recurrent infections prevented during the 12-month period. It was derived from the decision model and no discounting was applied.
Direct costs
Discounting was not relevant since the costs were incurred during less than 2 years. The unit costs and the quantities of resources used were presented separately. The health services included in the economic analysis were drugs, physician visits and surgical procedures. The cost/resource boundary of the payer was adopted. Resource use was estimated mainly using prospectively collected data derived from patients in the trial. Some assumptions were also made. The costs were estimated from wholesale prices and Medicare payments. The costs were presented in 2001 values, using the medical care component of the Consumer Price Index, when necessary.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs, such as time spent for transportation, waiting and examination, which were relevant to the patient, were included in the analysis. The unit costs were presented separately from the quantities of resources used. To estimate the time spent for transportation, distances were estimated using ZIP codes for clinics and patients. The time spent waiting for care and examination was derived from the Medical Expenditure Panel Survey. Average wages were used to assess the unit costs. Some resources, such as access to acyclovir care, treatment of recurrent infections, or surgical procedures, were based on authors' assumptions. Discounting was not relevant and the price year was 2001.
Currency

US dollars ($).
Sensitivity analysis
Univariate sensitivity analyses were conducted to assess the robustness of the cost-effectiveness ratios. The variables investigated were the daily cost of acyclovir, the probability of infection, and the probability of surgery given the occurrence of SK. The ranges of values used were based on the observed lowest and highest estimates. Two-way sensitivity analyses were conducted for the probabilities of infection in the placebo and treatment groups. All sensitivity analyses were carried out under two main scenarios in which the indirect costs were either included or excluded.
Estimated benefits used in the economic analysis
The number of recurrent infections was 0.461 with no prophylaxis, 0.226 with acyclovir for all patients, and 0.272 with acyclovir for patients with prior SK. Thus, acyclovir for all patients prevented 0.325 recurrent infections relative to no prophylaxis, and 0.046 recurrent infections relative to acyclovir for patients with prior SK.
Cost results
The total costs were $299 with no prophylaxis, $2,304 with acyclovir for all patients, and $2,329 with acyclovir for patients with prior SK.
The extra costs were $2,005 with acyclovir for all patients over no prophylaxis, and $25 for acyclovir for patients with prior SK over acyclovir for all patients.
